Premium
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias
Author(s) -
Kern Wolfgang,
Kohlmann Alexander,
Schoch Claudia,
Schnittger Susanne,
Haferlach Torsten
Publication year - 2006
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.22251
Subject(s) - microarray , immunophenotyping , microarray analysis techniques , cd117 , gene chip analysis , gene expression profiling , chronic leukemia , dna microarray , flow cytometry , medicine , cd34 , leukemia , acute leukemia , pathology , microbiology and biotechnology , biology , computational biology , gene expression , immunology , gene , genetics , stem cell
BACKGROUND. Microarray analysis is considered a future diagnostic tool in leukemias. Whereas data accumulate on specific gene expression patterns in biologically defined leukemia entities, data on the correlation between flow cytometrically determined protein expression, which are essential in the diagnostic setting today, and microarray results are limited. METHODS. The results obtained by microarray analysis were compared using the Affymetrix GeneChip HG‐U133 system in parallel with flow cytometric findings of 36 relevant targets in 814 patients with newly diagnosed acute and chronic leukemias as well as in normal bone marrow samples. RESULTS. In a total of 21,581 individual comparisons between signal intensities obtained by microarray analysis and percentages of positive cell as determined by flow cytometry, coefficients of correlation in the range of 0.171 to 0.807 were obtained. In particular, the degree of correlation was high in the following genes critical in the diagnostic setting: CD4, CD8, CD13 (ANPEP), CD33, CD23 (FCER2), CD64 (FCGR1A), CD117 (KIT), CD34, MPO, CD20 (MS4A1), CD7 (range of r , 0.589–0.807). CONCLUSIONS. The present data prove the high degree of correlation between findings obtained by microarray analysis and flow cytometry. They are in favor of a future application of the microarray technology as a robust diagnostic tool in leukemias. Cancer 2006. © 2006 American Cancer Society.